Guest Column | October 11, 2013

Fundamentals Of Viral Clearance Studies Part 5: How Much Is Enough?

Kathryn Martin Remington

By Kathryn Martin Remington, Ph.D., Principal Scientist for Clearance Services, BioReliance

A common concern for manufacturers of biopharmaceutical products is whether their process achieves sufficient viral clearance.   There is no fixed level of viral reduction that all manufacturing processes for biopharmaceutical products must achieve.   Each biopharmaceutical product uses unique source materials and a unique manufacturing process, and so each product has its own unique risk for potential viral transmission.  Therefore the level of viral reduction required to achieve an acceptable viral safety risk is specific to each product.  

VIEW THE GUEST COLUMN!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: